Autopsy report · NCT01312376
Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer
Cause of deathNo reason given
Life of this trial
- Ran for about 7 years 10 months before it stopped.
- 18 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- Abramson Cancer Center at Penn Medicine
- Sponsor type
- University, hospital or other
- Conditions
- Ovarian Carcinoma; Fallopian Tube Cancer; Primary Peritoneal Cancer
- Interventions
- OC-DC vaccine; Bevacizumab; cyclophosphamide 300 mg/m2/d for 3 days; fludarabine 30 mg/m2/d for 3 days; ex vivo CD3/CD28-costimulated vaccine-primed peripheral blood autologous T cells
- Participants
- 18
- Sites
- 1
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.